Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Fixed-dose combination of fosfomycin disodium and tobramycin

EU orphan designation number: EU/3/15/1538   
Active ingredient: Fixed-dose combination of fosfomycin disodium and tobramycin
Indication: Treatment of cystic fibrosis
Sponsor: CURx Pharma (UK) Limited
7th Floor, 16 St. Martin's-le-Grand, London EC1A 4EE, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/08/2015 Orphan designation EMA/OD/068/15 (2015)5774 of 10/08/2015